Schellens Ingrid M M, Borghans José A M, Jansen Christine A, De Cuyper Iris M, Geskus Ronald B, van Baarle Debbie, Miedema Frank
Department of Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
PLoS One. 2008 Jul 23;3(7):e2745. doi: 10.1371/journal.pone.0002745.
T-cell immunity is thought to play an important role in controlling HIV infection, and is a main target for HIV vaccine development. HIV-specific central memory CD8(+) and CD4(+) T cells producing IFNgamma and IL-2 have been associated with control of viremia and are therefore hypothesized to be truly protective and determine subsequent clinical outcome. However, the cause-effect relationship between HIV-specific cellular immunity and disease progression is unknown. We investigated in a large prospective cohort study involving 96 individuals of the Amsterdam Cohort Studies with a known date of seroconversion whether the presence of cytokine-producing HIV-specific CD8(+) T cells early in infection was associated with AIDS-free survival time.
The number and percentage of IFNgamma and IL-2 producing CD8(+) T cells was measured after in vitro stimulation with an overlapping Gag-peptide pool in T cells sampled approximately one year after seroconversion. Kaplan-Meier survival analysis and Cox proportional hazard models showed that frequencies of cytokine-producing Gag-specific CD8(+) T cells (IFNgamma, IL-2 or both) shortly after seroconversion were neither associated with time to AIDS nor with the rate of CD4(+) T-cell decline.
These data show that high numbers of functional HIV-specific CD8(+) T cells can be found early in HIV infection, irrespective of subsequent clinical outcome. The fact that both progressors and long-term non-progressors have abundant T cell immunity of the specificity associated with low viral load shortly after seroconversion suggests that the more rapid loss of T cell immunity observed in progressors may be a consequence rather than a cause of disease progression.
T 细胞免疫被认为在控制 HIV 感染中起重要作用,并且是 HIV 疫苗研发的主要靶点。产生 IFNγ 和 IL-2 的 HIV 特异性中枢记忆 CD8(+)和 CD4(+)T 细胞与病毒血症的控制有关,因此被假设为真正具有保护作用并决定后续临床结果。然而,HIV 特异性细胞免疫与疾病进展之间的因果关系尚不清楚。我们在一项大型前瞻性队列研究中进行了调查,该研究纳入了 96 名阿姆斯特丹队列研究中已知血清转化日期的个体,以确定感染早期产生细胞因子的 HIV 特异性 CD8(+)T 细胞的存在是否与无艾滋病生存时间相关。
在血清转化后约一年采集的 T 细胞中,用重叠的 Gag 肽池进行体外刺激后,测量产生 IFNγ 和 IL-2 的 CD8(+)T 细胞的数量和百分比。Kaplan-Meier 生存分析和 Cox 比例风险模型显示,血清转化后不久产生细胞因子的 Gag 特异性 CD8(+)T 细胞(IFNγ、IL-2 或两者)的频率与艾滋病发生时间和 CD4(+)T 细胞下降速率均无关。
这些数据表明,在 HIV 感染早期即可发现大量功能性 HIV 特异性 CD8(+)T 细胞,而与后续临床结果无关。血清转化后不久,疾病进展者和长期非进展者均具有与低病毒载量相关的特异性丰富 T 细胞免疫,这一事实表明,在疾病进展者中观察到的 T 细胞免疫更快丧失可能是疾病进展的结果而非原因。